Efficacy of DA-5204 on Gastroesophageal Reflux Disease
Status:
Completed
Trial end date:
2018-12-11
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double-blind, placebo-controlled clinical Study to
evaluate the efficacy of DA-5204 and proton pump inhibitor combination therapy compared with
proton pump inhibitor alone therapy in patients with gastroesophageal reflux Disease.